Redeye raises its base case for BONESUPORT following the Q2 2023 report, where our US CERAMENT G sales estimates were once again beaten. We reconsider our long-term sales outlook for CERAMENT G in the US while also assuming that the cannibalization of CERAMENT BVF will be more aggressive than previously expected.
LÄS MER
